Organoid Screening Platform A human organoid-based platform enables agnostic drug discovery and high-throughput screening, offering pharma partners a scalable route to test CNS targets with AI-assisted data analysis.

CNS Disease Focus Leading development programs in Huntington's Disease with expansion into neurodevelopment disorders present joint opportunities for disease-focused collaborators to co-develop or license targets and assays.

Brain-Penetrant Inhibitor Recent activity on a brain-penetrant BRD9 inhibitor suggests a concrete asset and collaboration path for organizations seeking CNS-active epigenetic modulators and IND-enabling work.

Flexible Collaboration With a compact team and a lean funding profile, Rumi Scientific can offer flexible engagement models including joint development programs, screening campaigns, and platform licensing.

Strategic Location Based in New York City, the company sits in a vibrant biotech corridor with access to academic partners, clinical networks, and local funding channels to accelerate partnerships.